Effect of Easy Sleep Complex Essential Oil Inhalation on Sleep Disorders

June 22, 2022 updated by: Chun-pai Yang, MD, Kuang Tien General Hospital
Sleep disorders affect human health tremendously. It has been reported that aromatherapy by fragrance inhalation can be used as an adjuvant therapy to modulate parasympathetic nervous activity for relieving stress and mood, and promoting sleep quality. Many researches confirmed that lavender essential oil can be used as an adjuvant therapy for sleep disorders. It can effectively relieve stress and modulate physical and mental status. However, many studies about aromatherapy lack sleep detection instruments to objectively confirm their effects on sleep physiology. Therefore, this study adopts Easy sleep complex essential oil as the experimental group. The lavender essential oil containing orange, petitgrain, rose, lavender, rosewood, ho wood, amyris essential oil and lavender oil is chosen as control group. The subjects will be randomly assigned to one of the two groups. The efficacy results will be evaluated and compared between the two groups. The investigators expect that aromatherapy by fragrance inhalation with Easy sleep complex essential oil will improve sleep quality more effectively than lavender essential oil.

Study Overview

Status

Completed

Conditions

Detailed Description

A Randomized, Single-blind, Active-Controlled Trial to Evaluate the aromatherapy by fragrance inhalation using Easy sleep complex essential oil in patients with sleep disorders.

Study Type

Interventional

Enrollment (Actual)

53

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taichung, Taiwan, 433
        • Kuang Tien General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 61 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The subjects who signs the informed consent form approved by the Institutional Review Board.
  • Adult between the ages of 20-65 with the ability to communicate and describe symptoms.
  • The subjects has sleep disorders that last for at least three months and more than three nights per week.
  • Pittsburgh Sleep Quality Index(PSQI) score greater than 5.
  • The subjects are willing to cooperate with the study requirements, examinations and tests, including aromatherapy, polysomnography for two consecutive nights, questionnaire and blood tests.

Exclusion Criteria:

  • The patients with abnormal olfactory system such as brain injury, acute or chronic sinusitis, and the history of nasal surgery.
  • Patients who are currently taking sedatives or stimulant medicine or food such as coffee or refresh drink.
  • Patients with a known history of allergy to aromatherapy or asthma.
  • Patients has severe cardiovascular or pulmonary disease (e.g., cardiac failure or lung failure), or has cancer or other critical illness (e.g., renal dialysis).
  • Pregnant or breastfeeding women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Easy sleep complex essential oil
Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
the aromatherapy by fragrance inhalation
Active Comparator: Lavender essential oil
Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
the aromatherapy by fragrance inhalation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Electroencephalogram (EEG)
Time Frame: 2 days
measure the alpha wave(8-14Hz), Vertex sharp wave(4-7Hz), K complex (negative- positive sharp component area), Spindle(7-14Hz for at least 0.5 sec), theta wave(4-7Hz), and delta wave(0.5-3Hz, amplitude>75uV).
2 days
Electrooculograph (EOG)
Time Frame: 2 days
a record of the difference in electrical charge between the front and back of the eye
2 days
Electrocardiogram (ECG)
Time Frame: 2 days
measure heart rate variability (HRV): change of R-R interval
2 days
Electromyogram (EMG)
Time Frame: 2 days
recording the electrical activity produced by skeletal muscles
2 days
Respiratory effort
Time Frame: 2 days
The amplitude change of chest and abdominal movement
2 days
Air flow
Time Frame: 2 days
The amplitude change of nasal pressure and thermistor
2 days
Blood pressure (mmHg)
Time Frame: 2 days
Systolic and Diastolic blood pressure
2 days
Blood oxygen saturation (the fraction of oxygen)
Time Frame: 2 days
saturated hemoglobin relative to total hemoglobin in the blood
2 days
Heart Rate (beats per minute)
Time Frame: 2 days
Rate of heart beat
2 days
The number of sleep gestures during the sleep
Time Frame: 2 days
Analyzed with video recording overnight
2 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Concentration of Interleukin-1
Time Frame: 2 days
blood test with fasting status
2 days
Concentration of Interleukin-6
Time Frame: 2 days
blood test with fasting status
2 days
Concentration of Interleukin-8
Time Frame: 2 days
blood test with fasting status
2 days
Concentration of Tumor necrosis factor-alpha
Time Frame: 2 days
blood test with fasting status
2 days
Concentration of Malonaldehyde
Time Frame: 2 days
Indicator of oxidative stress
2 days
Concentration of Total antioxidant capacity
Time Frame: 2 days
Indicator of oxidative stress
2 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 4, 2019

Primary Completion (Actual)

January 17, 2022

Study Completion (Actual)

January 17, 2022

Study Registration Dates

First Submitted

April 23, 2019

First Submitted That Met QC Criteria

April 28, 2019

First Posted (Actual)

May 1, 2019

Study Record Updates

Last Update Posted (Actual)

June 23, 2022

Last Update Submitted That Met QC Criteria

June 22, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe